Summary

The global Transdermal Drug Delivery Formulation market is projected to grow from US$ 8015 million in 2025 to US$ 11349 million by 2032, at a CAGR of 5.1% (2026-2032), driven by critical product segments and diverse end‑use applications.
Transdermal Drug Delivery Formulation refers to pharmaceutical formulations designed to deliver active drug ingredients across the skin barrier into systemic circulation or localized target tissues through controlled release mechanisms. The research scope focuses on formulation technologies and dosage forms such as transdermal patches, matrix systems, reservoir systems, drug-in-adhesive systems, gels, creams, and emerging microneedle-based formulations. These formulations are engineered to improve drug stability, enhance skin permeability, maintain therapeutic concentrations, and provide convenient administration compared with conventional oral or injectable routes. Transdermal Drug Delivery Formulation is primarily applied in chronic disease management, pain treatment, hormone therapy, neurological disorders, cardiovascular therapies, smoking cessation, and other pharmaceutical treatment areas.
Key Findings
Global demand focuses on chronic therapy and patient-friendly delivery
Transdermal patches remain the core commercial formulation segment
North America represents a major established regional market
Pain management is a leading therapeutic application area
Advanced delivery technologies expand formulation innovation opportunities
Market Trends
The Transdermal Drug Delivery Formulation industry is moving from traditional patch-based delivery toward advanced drug release platforms with improved permeability, precision, and patient compliance. Pharmaceutical companies are increasingly focusing on formulation optimization, including polymer matrix technologies, adhesive innovation, penetration enhancement systems, and microneedle-based approaches. The market direction is shifting from simple sustained release toward multifunctional delivery platforms capable of supporting complex molecules, personalized treatment requirements, and long-term disease management. As healthcare systems place greater emphasis on outpatient treatment and self-administration, convenient and non-invasive delivery technologies are expected to gain increasing attention across pharmaceutical development pipelines.
Market Dynamics
Drivers
The growth of Transdermal Drug Delivery Formulation is supported by increasing demand for chronic disease therapies, aging populations, and the need for improved medication adherence. Compared with traditional administration routes, transdermal systems provide advantages such as controlled drug release, reduced dosing frequency, and improved patient convenience. Expanding applications in pain management, hormone replacement therapy, neurological treatment, and smoking cessation continue to support commercial adoption.
Restraints
Market development is constrained by formulation complexity, limited skin permeability for many active pharmaceutical ingredients, and higher development requirements compared with conventional dosage forms. Drug candidates must meet strict requirements regarding molecular size, solubility, stability, and skin absorption characteristics. Manufacturing consistency, adhesive performance, and regulatory requirements also increase commercialization challenges.
Opportunities
Future opportunities are emerging from advanced transdermal technologies, including microneedle delivery, enhanced permeation systems, and combination formulations. Increasing pharmaceutical investment in biologics, peptides, and difficult-to-deliver molecules creates demand for innovative delivery approaches. Expansion of home healthcare and self-administration models also provides new application opportunities for transdermal platforms.
Challenges
The industry faces challenges related to technology commercialization, regulatory approval complexity, and competition from alternative delivery technologies such as oral controlled-release formulations and injectable systems. Achieving sufficient drug delivery efficiency while maintaining safety and patient comfort remains a key technical challenge for next-generation Transdermal Drug Delivery Formulation products.
Industry Chain Analysis
The Transdermal Drug Delivery Formulation industry includes upstream pharmaceutical raw materials, functional excipients, polymers, adhesives, penetration enhancers, and specialized manufacturing materials. These components determine formulation performance, drug release characteristics, skin permeability, and product stability. The middle segment consists of pharmaceutical developers, formulation technology providers, and manufacturers responsible for drug formulation design, clinical development, regulatory compliance, and commercial production.
The downstream value chain is mainly driven by pharmaceutical companies, healthcare providers, and patients across prescription and self-care treatment scenarios. Value creation is concentrated in formulation technology, intellectual property protection, manufacturing capability, regulatory expertise, and clinical application development. Companies with advanced delivery platforms and scalable manufacturing capabilities are better positioned to capture long-term market opportunities.
Segment Insights
The Transdermal Drug Delivery Formulation market is structured around multiple formulation technologies, with transdermal patches representing the most mature commercial segment due to established manufacturing processes and broad clinical acceptance. Drug-in-adhesive and matrix-based systems maintain strong market positions because of their simplified structures, reliable release performance, and suitability for various therapeutic applications.
Emerging segments such as microneedle-based transdermal formulations and advanced active delivery systems are gaining attention due to their potential to overcome traditional skin barrier limitations. These technologies are expected to create additional opportunities in areas requiring higher delivery efficiency, complex drug molecules, and improved therapeutic precision.
Downstream Market Opportunities
The major downstream opportunities for Transdermal Drug Delivery Formulation are concentrated in pharmaceutical treatment areas requiring long-term therapy, stable drug exposure, and improved patient compliance. Pain management remains one of the most commercially developed application areas, while hormone therapy, neurological disorders, cardiovascular treatment, and smoking cessation continue to provide stable demand. Future opportunities are expected from home-based healthcare models and patient-centered treatment approaches that favor convenient non-invasive administration methods.
Regional Insights
North America represents one of the largest established markets for Transdermal Drug Delivery Formulation, supported by advanced pharmaceutical development capabilities, strong healthcare infrastructure, and widespread adoption of innovative drug delivery technologies. The region maintains significant demand for prescription transdermal products and advanced formulation research.
Europe also represents a mature market with strong pharmaceutical manufacturing capabilities and regulatory support for advanced drug delivery systems. Asia-Pacific is expected to demonstrate faster expansion potential driven by increasing healthcare expenditure, pharmaceutical industry development, and growing demand for chronic disease treatment solutions. Regional differences mainly reflect healthcare accessibility, pharmaceutical innovation capacity, regulatory environments, and patient acceptance of non-invasive delivery methods.
Competitive Landscape Analysis
The Transdermal Drug Delivery Formulation market features competition among pharmaceutical companies, drug delivery technology developers, and specialized formulation manufacturers. Market participants differentiate through proprietary formulation technologies, drug release control capabilities, adhesive technologies, manufacturing expertise, and regulatory experience. Established pharmaceutical companies generally focus on commercialized therapeutic products and lifecycle management, while specialized delivery technology companies emphasize platform innovation and partnerships with pharmaceutical developers. Competitive advantages are increasingly determined by formulation performance, intellectual property capabilities, manufacturing reliability, and the ability to address emerging therapeutic requirements.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Transdermal Drug Delivery Formulation market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Hisamitsu
Viatris
GSK
Novartis
Teva
Johnson & Johnson
UCB
Teikoku Seiyaku
Bayer
LingRui Pharma
Sanofi
Qizheng Pharma
Endo
CR Sanjiu
Haw Par
Nichiban
Mentholatum Company
Nitto Denko
Segment by Type
Fentanyl
Nitroglycerin
Estradiol
Nicotine
Other
Segment by Drugs
OTC
Rx
Segment by Technology
Matrix Patch
Reservoir Patch
Drug-in-Adhesive Patch
Other
Segment by Application
Hospital
Drug Store
Other
Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Transdermal Drug Delivery Formulation study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Transdermal Drug Delivery Formulation: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Transdermal Drug Delivery Formulation Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Fentanyl
1.2.3 Nitroglycerin
1.2.4 Estradiol
1.2.5 Nicotine
1.2.6 Other
1.3 Market Segmentation by Drugs
1.3.1 Global Transdermal Drug Delivery Formulation Market Size by Drugs, 2021 vs 2025 vs 2032
1.3.2 OTC
1.3.3 Rx
1.4 Market Segmentation by Technology
1.4.1 Global Transdermal Drug Delivery Formulation Market Size by Technology, 2021 vs 2025 vs 2032
1.4.2 Matrix Patch
1.4.3 Reservoir Patch
1.4.4 Drug-in-Adhesive Patch
1.4.5 Other
1.5 Market Segmentation by Application
1.5.1 Global Transdermal Drug Delivery Formulation Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Hospital
1.5.3 Drug Store
1.5.4 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Transdermal Drug Delivery Formulation Revenue Estimates and Forecasts (2021-2032)
2.2 Global Transdermal Drug Delivery Formulation Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Transdermal Drug Delivery Formulation Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Transdermal Drug Delivery Formulation Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 Fentanyl: Market Share by Key Players
3.3.2 Nitroglycerin: Market Share by Key Players
3.3.3 Estradiol: Market Share by Key Players
3.3.4 Nicotine: Market Share by Key Players
3.3.5 Other: Market Share by Key Players
3.4 Global Transdermal Drug Delivery Formulation Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Transdermal Drug Delivery Formulation Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Transdermal Drug Delivery Formulation Market by Drugs
4.2.1 Global Revenue by Drugs (2021-2032)
4.2.2 Global Revenue-Based Market Share by Drugs (2021-2032)
4.3 Global Transdermal Drug Delivery Formulation Market by Technology
4.3.1 Global Revenue by Technology (2021-2032)
4.3.2 Global Revenue-Based Market Share by Technology (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Transdermal Drug Delivery Formulation Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Transdermal Drug Delivery Formulation Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Transdermal Drug Delivery Formulation Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Transdermal Drug Delivery Formulation Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Transdermal Drug Delivery Formulation Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Transdermal Drug Delivery Formulation Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Transdermal Drug Delivery Formulation Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Transdermal Drug Delivery Formulation Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Transdermal Drug Delivery Formulation Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Transdermal Drug Delivery Formulation Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Transdermal Drug Delivery Formulation Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Hisamitsu
11.1.1 Hisamitsu Corporation Information
11.1.2 Hisamitsu Business Overview
11.1.3 Hisamitsu Transdermal Drug Delivery Formulation Product Features and Attributes
11.1.4 Hisamitsu Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.1.5 Hisamitsu Transdermal Drug Delivery Formulation Revenue by Product in 2025
11.1.6 Hisamitsu Transdermal Drug Delivery Formulation Revenue by Application in 2025
11.1.7 Hisamitsu Transdermal Drug Delivery Formulation Revenue by Geographic Area in 2025
11.1.8 Hisamitsu Transdermal Drug Delivery Formulation SWOT Analysis
11.1.9 Hisamitsu Recent Developments
11.2 Viatris
11.2.1 Viatris Corporation Information
11.2.2 Viatris Business Overview
11.2.3 Viatris Transdermal Drug Delivery Formulation Product Features and Attributes
11.2.4 Viatris Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.2.5 Viatris Transdermal Drug Delivery Formulation Revenue by Product in 2025
11.2.6 Viatris Transdermal Drug Delivery Formulation Revenue by Application in 2025
11.2.7 Viatris Transdermal Drug Delivery Formulation Revenue by Geographic Area in 2025
11.2.8 Viatris Transdermal Drug Delivery Formulation SWOT Analysis
11.2.9 Viatris Recent Developments
11.3 GSK
11.3.1 GSK Corporation Information
11.3.2 GSK Business Overview
11.3.3 GSK Transdermal Drug Delivery Formulation Product Features and Attributes
11.3.4 GSK Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.3.5 GSK Transdermal Drug Delivery Formulation Revenue by Product in 2025
11.3.6 GSK Transdermal Drug Delivery Formulation Revenue by Application in 2025
11.3.7 GSK Transdermal Drug Delivery Formulation Revenue by Geographic Area in 2025
11.3.8 GSK Transdermal Drug Delivery Formulation SWOT Analysis
11.3.9 GSK Recent Developments
11.4 Novartis
11.4.1 Novartis Corporation Information
11.4.2 Novartis Business Overview
11.4.3 Novartis Transdermal Drug Delivery Formulation Product Features and Attributes
11.4.4 Novartis Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.4.5 Novartis Transdermal Drug Delivery Formulation Revenue by Product in 2025
11.4.6 Novartis Transdermal Drug Delivery Formulation Revenue by Application in 2025
11.4.7 Novartis Transdermal Drug Delivery Formulation Revenue by Geographic Area in 2025
11.4.8 Novartis Transdermal Drug Delivery Formulation SWOT Analysis
11.4.9 Novartis Recent Developments
11.5 Teva
11.5.1 Teva Corporation Information
11.5.2 Teva Business Overview
11.5.3 Teva Transdermal Drug Delivery Formulation Product Features and Attributes
11.5.4 Teva Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.5.5 Teva Transdermal Drug Delivery Formulation Revenue by Product in 2025
11.5.6 Teva Transdermal Drug Delivery Formulation Revenue by Application in 2025
11.5.7 Teva Transdermal Drug Delivery Formulation Revenue by Geographic Area in 2025
11.5.8 Teva Transdermal Drug Delivery Formulation SWOT Analysis
11.5.9 Teva Recent Developments
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Corporation Information
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Transdermal Drug Delivery Formulation Product Features and Attributes
11.6.4 Johnson & Johnson Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.6.5 Johnson & Johnson Recent Developments
11.7 UCB
11.7.1 UCB Corporation Information
11.7.2 UCB Business Overview
11.7.3 UCB Transdermal Drug Delivery Formulation Product Features and Attributes
11.7.4 UCB Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.7.5 UCB Recent Developments
11.8 Teikoku Seiyaku
11.8.1 Teikoku Seiyaku Corporation Information
11.8.2 Teikoku Seiyaku Business Overview
11.8.3 Teikoku Seiyaku Transdermal Drug Delivery Formulation Product Features and Attributes
11.8.4 Teikoku Seiyaku Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.8.5 Teikoku Seiyaku Recent Developments
11.9 Bayer
11.9.1 Bayer Corporation Information
11.9.2 Bayer Business Overview
11.9.3 Bayer Transdermal Drug Delivery Formulation Product Features and Attributes
11.9.4 Bayer Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.9.5 Bayer Recent Developments
11.10 LingRui Pharma
11.10.1 LingRui Pharma Corporation Information
11.10.2 LingRui Pharma Business Overview
11.10.3 LingRui Pharma Transdermal Drug Delivery Formulation Product Features and Attributes
11.10.4 LingRui Pharma Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Sanofi
11.11.1 Sanofi Corporation Information
11.11.2 Sanofi Business Overview
11.11.3 Sanofi Transdermal Drug Delivery Formulation Product Features and Attributes
11.11.4 Sanofi Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.11.5 Sanofi Recent Developments
11.12 Qizheng Pharma
11.12.1 Qizheng Pharma Corporation Information
11.12.2 Qizheng Pharma Business Overview
11.12.3 Qizheng Pharma Transdermal Drug Delivery Formulation Product Features and Attributes
11.12.4 Qizheng Pharma Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.12.5 Qizheng Pharma Recent Developments
11.13 Endo
11.13.1 Endo Corporation Information
11.13.2 Endo Business Overview
11.13.3 Endo Transdermal Drug Delivery Formulation Product Features and Attributes
11.13.4 Endo Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.13.5 Endo Recent Developments
11.14 CR Sanjiu
11.14.1 CR Sanjiu Corporation Information
11.14.2 CR Sanjiu Business Overview
11.14.3 CR Sanjiu Transdermal Drug Delivery Formulation Product Features and Attributes
11.14.4 CR Sanjiu Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.14.5 CR Sanjiu Recent Developments
11.15 Haw Par
11.15.1 Haw Par Corporation Information
11.15.2 Haw Par Business Overview
11.15.3 Haw Par Transdermal Drug Delivery Formulation Product Features and Attributes
11.15.4 Haw Par Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.15.5 Haw Par Recent Developments
11.16 Nichiban
11.16.1 Nichiban Corporation Information
11.16.2 Nichiban Business Overview
11.16.3 Nichiban Transdermal Drug Delivery Formulation Product Features and Attributes
11.16.4 Nichiban Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.16.5 Nichiban Recent Developments
11.17 Mentholatum Company
11.17.1 Mentholatum Company Corporation Information
11.17.2 Mentholatum Company Business Overview
11.17.3 Mentholatum Company Transdermal Drug Delivery Formulation Product Features and Attributes
11.17.4 Mentholatum Company Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.17.5 Mentholatum Company Recent Developments
11.18 Nitto Denko
11.18.1 Nitto Denko Corporation Information
11.18.2 Nitto Denko Business Overview
11.18.3 Nitto Denko Transdermal Drug Delivery Formulation Product Features and Attributes
11.18.4 Nitto Denko Transdermal Drug Delivery Formulation Revenue and Gross Margin (2021-2026)
11.18.5 Nitto Denko Recent Developments

12 Transdermal Drug Delivery Formulation Value Chain and Ecosystem Analysis
12.1 Transdermal Drug Delivery Formulation Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Transdermal Drug Delivery Formulation Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Transdermal Drug Delivery Formulation Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Transdermal Drug Delivery Formulation Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Transdermal Drug Delivery Formulation Market Size Growth Rate by Drugs, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Transdermal Drug Delivery Formulation Market Size Growth Rate by Technology, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Transdermal Drug Delivery Formulation Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Transdermal Drug Delivery Formulation Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Transdermal Drug Delivery Formulation Revenue by Region (US$ Million), 2021-2026
Table 7. Global Transdermal Drug Delivery Formulation Revenue by Region (US$ Million), 2027-2032
Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 9. Global Transdermal Drug Delivery Formulation Revenue by Players (US$ Million), 2021-2026
Table 10. Global Transdermal Drug Delivery Formulation Revenue-Based Market Share by Players (2021-2026)
Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Transdermal Drug Delivery Formulation Revenue, 2025
Table 13. Global Transdermal Drug Delivery Formulation Average Gross Margin (%) by Player (2021 vs 2025)
Table 14. Global Transdermal Drug Delivery Formulation Companies Headquarters
Table 15. Global Transdermal Drug Delivery Formulation Market Concentration Ratio (CR5)
Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 18. Global Transdermal Drug Delivery Formulation Revenue by Type (US$ Million), 2021-2026
Table 19. Global Transdermal Drug Delivery Formulation Revenue by Type (US$ Million), 2027-2032
Table 20. Global Transdermal Drug Delivery Formulation Revenue by Drugs (US$ Million), 2021-2026
Table 21. Global Transdermal Drug Delivery Formulation Revenue by Drugs (US$ Million), 2027-2032
Table 22. Global Transdermal Drug Delivery Formulation Revenue by Technology (US$ Million), 2021-2026
Table 23. Global Transdermal Drug Delivery Formulation Revenue by Technology (US$ Million), 2027-2032
Table 24. Key Product Attributes and Differentiation
Table 25. Global Transdermal Drug Delivery Formulation Revenue by Application (US$ Million), 2021-2026
Table 26. Global Transdermal Drug Delivery Formulation Revenue by Application (US$ Million), 2027-2032
Table 27. Transdermal Drug Delivery Formulation High-Growth Sectors Demand CAGR (2026-2032)
Table 28. Top Customers by Region
Table 29. Top Customers by Application
Table 30. North America Transdermal Drug Delivery Formulation Growth Accelerators and Market Barriers
Table 31. North America Transdermal Drug Delivery Formulation Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 32. Europe Transdermal Drug Delivery Formulation Growth Accelerators and Market Barriers
Table 33. Europe Transdermal Drug Delivery Formulation Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Asia-Pacific Transdermal Drug Delivery Formulation Growth Accelerators and Market Barriers
Table 35. Asia-Pacific Transdermal Drug Delivery Formulation Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Central and South America Transdermal Drug Delivery Formulation Investment Opportunities and Key Challenges
Table 37. Central and South America Transdermal Drug Delivery Formulation Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 38. Middle East and Africa Transdermal Drug Delivery Formulation Investment Opportunities and Key Challenges
Table 39. Middle East and Africa Transdermal Drug Delivery Formulation Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 40. Hisamitsu Corporation Information
Table 41. Hisamitsu Description and Major Businesses
Table 42. Hisamitsu Product Features and Attributes
Table 43. Hisamitsu Revenue (US$ Million) and Gross Margin (2021-2026)
Table 44. Hisamitsu Revenue Proportion by Product in 2025
Table 45. Hisamitsu Revenue Proportion by Application in 2025
Table 46. Hisamitsu Revenue Proportion by Geographic Area in 2025
Table 47. Hisamitsu Transdermal Drug Delivery Formulation SWOT Analysis
Table 48. Hisamitsu Recent Developments
Table 49. Viatris Corporation Information
Table 50. Viatris Description and Major Businesses
Table 51. Viatris Product Features and Attributes
Table 52. Viatris Revenue (US$ Million) and Gross Margin (2021-2026)
Table 53. Viatris Revenue Proportion by Product in 2025
Table 54. Viatris Revenue Proportion by Application in 2025
Table 55. Viatris Revenue Proportion by Geographic Area in 2025
Table 56. Viatris Transdermal Drug Delivery Formulation SWOT Analysis
Table 57. Viatris Recent Developments
Table 58. GSK Corporation Information
Table 59. GSK Description and Major Businesses
Table 60. GSK Product Features and Attributes
Table 61. GSK Revenue (US$ Million) and Gross Margin (2021-2026)
Table 62. GSK Revenue Proportion by Product in 2025
Table 63. GSK Revenue Proportion by Application in 2025
Table 64. GSK Revenue Proportion by Geographic Area in 2025
Table 65. GSK Transdermal Drug Delivery Formulation SWOT Analysis
Table 66. GSK Recent Developments
Table 67. Novartis Corporation Information
Table 68. Novartis Description and Major Businesses
Table 69. Novartis Product Features and Attributes
Table 70. Novartis Revenue (US$ Million) and Gross Margin (2021-2026)
Table 71. Novartis Revenue Proportion by Product in 2025
Table 72. Novartis Revenue Proportion by Application in 2025
Table 73. Novartis Revenue Proportion by Geographic Area in 2025
Table 74. Novartis Transdermal Drug Delivery Formulation SWOT Analysis
Table 75. Novartis Recent Developments
Table 76. Teva Corporation Information
Table 77. Teva Description and Major Businesses
Table 78. Teva Product Features and Attributes
Table 79. Teva Revenue (US$ Million) and Gross Margin (2021-2026)
Table 80. Teva Revenue Proportion by Product in 2025
Table 81. Teva Revenue Proportion by Application in 2025
Table 82. Teva Revenue Proportion by Geographic Area in 2025
Table 83. Teva Transdermal Drug Delivery Formulation SWOT Analysis
Table 84. Teva Recent Developments
Table 85. Johnson & Johnson Corporation Information
Table 86. Johnson & Johnson Description and Major Businesses
Table 87. Johnson & Johnson Product Features and Attributes
Table 88. Johnson & Johnson Revenue (US$ Million) and Gross Margin (2021-2026)
Table 89. Johnson & Johnson Recent Developments
Table 90. UCB Corporation Information
Table 91. UCB Description and Major Businesses
Table 92. UCB Product Features and Attributes
Table 93. UCB Revenue (US$ Million) and Gross Margin (2021-2026)
Table 94. UCB Recent Developments
Table 95. Teikoku Seiyaku Corporation Information
Table 96. Teikoku Seiyaku Description and Major Businesses
Table 97. Teikoku Seiyaku Product Features and Attributes
Table 98. Teikoku Seiyaku Revenue (US$ Million) and Gross Margin (2021-2026)
Table 99. Teikoku Seiyaku Recent Developments
Table 100. Bayer Corporation Information
Table 101. Bayer Description and Major Businesses
Table 102. Bayer Product Features and Attributes
Table 103. Bayer Revenue (US$ Million) and Gross Margin (2021-2026)
Table 104. Bayer Recent Developments
Table 105. LingRui Pharma Corporation Information
Table 106. LingRui Pharma Description and Major Businesses
Table 107. LingRui Pharma Product Features and Attributes
Table 108. LingRui Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 109. LingRui Pharma Recent Developments
Table 110. Sanofi Corporation Information
Table 111. Sanofi Description and Major Businesses
Table 112. Sanofi Product Features and Attributes
Table 113. Sanofi Revenue (US$ Million) and Gross Margin (2021-2026)
Table 114. Sanofi Recent Developments
Table 115. Qizheng Pharma Corporation Information
Table 116. Qizheng Pharma Description and Major Businesses
Table 117. Qizheng Pharma Product Features and Attributes
Table 118. Qizheng Pharma Revenue (US$ Million) and Gross Margin (2021-2026)
Table 119. Qizheng Pharma Recent Developments
Table 120. Endo Corporation Information
Table 121. Endo Description and Major Businesses
Table 122. Endo Product Features and Attributes
Table 123. Endo Revenue (US$ Million) and Gross Margin (2021-2026)
Table 124. Endo Recent Developments
Table 125. CR Sanjiu Corporation Information
Table 126. CR Sanjiu Description and Major Businesses
Table 127. CR Sanjiu Product Features and Attributes
Table 128. CR Sanjiu Revenue (US$ Million) and Gross Margin (2021-2026)
Table 129. CR Sanjiu Recent Developments
Table 130. Haw Par Corporation Information
Table 131. Haw Par Description and Major Businesses
Table 132. Haw Par Product Features and Attributes
Table 133. Haw Par Revenue (US$ Million) and Gross Margin (2021-2026)
Table 134. Haw Par Recent Developments
Table 135. Nichiban Corporation Information
Table 136. Nichiban Description and Major Businesses
Table 137. Nichiban Product Features and Attributes
Table 138. Nichiban Revenue (US$ Million) and Gross Margin (2021-2026)
Table 139. Nichiban Recent Developments
Table 140. Mentholatum Company Corporation Information
Table 141. Mentholatum Company Description and Major Businesses
Table 142. Mentholatum Company Product Features and Attributes
Table 143. Mentholatum Company Revenue (US$ Million) and Gross Margin (2021-2026)
Table 144. Mentholatum Company Recent Developments
Table 145. Nitto Denko Corporation Information
Table 146. Nitto Denko Description and Major Businesses
Table 147. Nitto Denko Product Features and Attributes
Table 148. Nitto Denko Revenue (US$ Million) and Gross Margin (2021-2026)
Table 149. Nitto Denko Recent Developments
Table 150. Technologies, Platforms and Infrastructure
Table 151. Distributors List
Table 152. Market Trends and Market Evolution
Table 153. Market Drivers and Opportunities
Table 154. Market Challenges, Risks, and Restraints
Table 155. Research Programs/Design for This Report
Table 156. Key Data Information from Secondary Sources
Table 157. Key Data Information from Primary Sources

List of Figures
Figure 1. Global Transdermal Drug Delivery Formulation Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 2. Fentanyl Product Picture
Figure 3. Nitroglycerin Product Picture
Figure 4. Estradiol Product Picture
Figure 5. Nicotine Product Picture
Figure 6. Other Product Picture
Figure 7. Global Transdermal Drug Delivery Formulation Market Size Growth Rate by Drugs, 2021 vs 2025 vs 2032 (US$ Million)
Figure 8. OTC Product Picture
Figure 9. Rx Product Picture
Figure 10. Global Transdermal Drug Delivery Formulation Market Size Growth Rate by Technology, 2021 vs 2025 vs 2032 (US$ Million)
Figure 11. Matrix Patch Product Picture
Figure 12. Reservoir Patch Product Picture
Figure 13. Drug-in-Adhesive Patch Product Picture
Figure 14. Other Product Picture
Figure 15. Global Transdermal Drug Delivery Formulation Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 16. Hospital
Figure 17. Drug Store
Figure 18. Other
Figure 19. Transdermal Drug Delivery Formulation Report Years Considered
Figure 20. Global Transdermal Drug Delivery Formulation Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 21. Global Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 22. Global Transdermal Drug Delivery Formulation Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 23. Global Transdermal Drug Delivery Formulation Revenue-Based Market Share by Region (2021-2032)
Figure 24. Global Transdermal Drug Delivery Formulation Revenue-Based Market Share Ranking (2025)
Figure 25. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 26. Fentanyl Revenue-Based Market Share by Player in 2025
Figure 27. Nitroglycerin Revenue-Based Market Share by Player in 2025
Figure 28. Estradiol Revenue-Based Market Share by Player in 2025
Figure 29. Nicotine Revenue-Based Market Share by Player in 2025
Figure 30. Other Revenue-Based Market Share by Player in 2025
Figure 31. Global Transdermal Drug Delivery Formulation Revenue-Based Market Share by Type (2021-2032)
Figure 32. Global Transdermal Drug Delivery Formulation Revenue-Based Market Share by Drugs (2021-2032)
Figure 33. Global Transdermal Drug Delivery Formulation Revenue-Based Market Share by Technology (2021-2032)
Figure 34. Global Transdermal Drug Delivery Formulation Revenue-Based Market Share by Application (2021-2032)
Figure 35. North America Transdermal Drug Delivery Formulation Revenue YoY (US$ Million), 2021-2032
Figure 36. North America Top 5 Players Transdermal Drug Delivery Formulation Revenue (US$ Million) in 2025
Figure 37. North America Transdermal Drug Delivery Formulation Revenue (US$ Million) by Application (2021-2032)
Figure 38. US Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 39. Canada Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 40. Mexico Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 41. Europe Transdermal Drug Delivery Formulation Revenue YoY (US$ Million), 2021-2032
Figure 42. Europe Top 5 Players Transdermal Drug Delivery Formulation Revenue (US$ Million) in 2025
Figure 43. Europe Transdermal Drug Delivery Formulation Revenue (US$ Million) by Application (2021-2032)
Figure 44. Germany Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 45. France Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 46. U.K. Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 47. Italy Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 48. Russia Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 49. Asia-Pacific Transdermal Drug Delivery Formulation Revenue YoY (US$ Million), 2021-2032
Figure 50. Asia-Pacific Top 8 Players Transdermal Drug Delivery Formulation Revenue (US$ Million) in 2025
Figure 51. Asia-Pacific Transdermal Drug Delivery Formulation Revenue (US$ Million) by Application (2021-2032)
Figure 52. Indonesia Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 53. Japan Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 54. South Korea Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 55. Australia Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 56. India Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 57. Indonesia Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 58. Vietnam Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 59. Malaysia Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 60. Philippines Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 61. Singapore Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 62. Central and South America Transdermal Drug Delivery Formulation Revenue YoY (US$ Million), 2021-2032
Figure 63. Central and South America Top 5 Players Transdermal Drug Delivery Formulation Revenue (US$ Million) in 2025
Figure 64. Central and South America Transdermal Drug Delivery Formulation Revenue (US$ Million) by Application (2021-2032)
Figure 65. Brazil Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 66. Argentina Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 67. Middle East and Africa Transdermal Drug Delivery Formulation Revenue YoY (US$ Million), 2021-2032
Figure 68. Middle East and Africa Top 5 Players Transdermal Drug Delivery Formulation Revenue (US$ Million) in 2025
Figure 69. Middle East and Africa Transdermal Drug Delivery Formulation Revenue (US$ Million) by Application (2021-2032)
Figure 70. GCC Countries Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 71. Israel Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 72. Egypt Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 73. South Africa Transdermal Drug Delivery Formulation Revenue (US$ Million), 2021-2032
Figure 74. Transdermal Drug Delivery Formulation Value Chain Mapping
Figure 75. Channels of Distribution (Direct Vs Distribution)
Figure 76. Bottom-up and Top-down Approaches for This Report
Figure 77. Data Triangulation
Figure 78. Key Executives Interviewed